Atorvastatin

Generic Name: Atorvastatin

Brand Names: Atorvaliq, Caduet, Lipitor, Lypqozet

Drug Type: Small Molecule

Chemical Formula: C_₃₃H_₃₅FN_₂O_₅

CAS Number: 134523-00-5

Unique Ingredient Identifier: A0JWA85V8F

Background: Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylg...

Indication: Atorvastatin is indicated for the treatment of several types of dyslipidemias, including primary hyperlipidemia and mixed dyslipidemia in adults, hypertriglyceridemia, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia, and heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modifications.
...

Associated Conditions: Anginal Pain, Cardiovascular Complications, Cardiovascular Disease (CVD), Coronary Artery Disease (CAD), Coronary artery thrombosis, Dysbetalipoproteinemia, Fredrickson Type III lipidemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hospitalizations, Hypertension, Essential Hypertension, Hypertriglyceridemias, Mixed Dyslipidemias, Mixed Hyperlipidemia, Myocardial Infarction, Non-familial hypercholesterolemia, Nonfatal Myocardial Infarction, Postoperative Thromboembolism, Primary Hypercholesterolemia, Stroke, Thrombosis, Transient Ischemic Attack, Elevation of serum triglyceride levels, Heterozygous familial hyperlipidemia, Non-familial hyperlipidemia, Primary Hyperlipidemia, Revascularization procedures

Associated Therapies: -

Clinical Trials

STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS

Phase 1

Completed

Conditions: Healthy Adults

Interventions: Drug: PF-06882961
Drug: Levonorgestrel & Ethinyl Estradiol
Drug: Atorvastatin
Drug: Midazolam

First Posted Date: 2021-10-26

Last Posted Date: 2024-08-19

Lead Sponsor: Pfizer

Target Recruit Count: 35

Registration Number: NCT05093205

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States

ALT-801 DDI Study in Healthy Volunteers

Phase 1

Completed

Conditions: NASH - Nonalcoholic Steatohepatitis

Interventions: Drug: ALT-801
Drug: Ethinylestradiol and Levonorgestrel
Drug: Metformin
Drug: Warfarin
Drug: Atorvastatin
Drug: Digoxin

First Posted Date: 2021-07-22

Last Posted Date: 2022-12-08

Lead Sponsor: Altimmune, Inc.

Target Recruit Count: 40

Registration Number: NCT04972396

Locations: 🇦🇺
Q-Pharm, Herston, Queensland, Australia
🇦🇺
CMAX Clinical Research, Adelaide, South Australia, Australia

Comparison of Atorvastatin and Pitavastatin on the Effect of HbA1c in AMI Patients With Abnormal Glucose Metabolism

Phase 4

Conditions: Acute Myocardial Infarction
Glucose Metabolism Disorders

Interventions: Drug: Pitavastatin
Drug: Atorvastatin

First Posted Date: 2021-06-30

Last Posted Date: 2022-05-12

Lead Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital

Target Recruit Count: 900

Registration Number: NCT04945122

Locations: 🇨🇳
Fuwai Hospital, Beijing, Beijing, China

Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men

Phase 1

Withdrawn

Conditions: Hypertension
Hyperlipidemias

Interventions: Drug: Atorvastatin
Other: placebo

First Posted Date: 2021-06-10

Last Posted Date: 2022-11-03

Lead Sponsor: Yale University

Registration Number: NCT04922424

Locations: 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

Phase 2

Recruiting

Conditions: Hearing Loss
Head and Neck Cancer

Interventions: Drug: Atorvastatin
Other: Placebo

First Posted Date: 2021-06-07

Last Posted Date: 2024-08-09

Lead Sponsor: National Institute on Deafness and Other Communication Disorders (NIDCD)

Target Recruit Count: 214

Registration Number: NCT04915183

Locations: 🇺🇸
Winship Cancer Institute at Emory University, Atlanta, Georgia, United States
🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

and more 1 locations